Iterum Therapeutics plc (ITRMF) Liabilities and Shareholders Equity (2017 - 2025)

Iterum Therapeutics' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $32.5 million for Q3 2025.

• In Q3 2025, Liabilities and Shareholders Equity rose 104.11% year-over-year to $32.5 million; the TTM figure through Sep 2025 stood at $144.1 million (up 89.63% YoY), while the FY2024 annual figure was $44.6 million, up 69.83% from the prior year.
• Liabilities and Shareholders Equity for Q3 2025 stood at $32.5 million, down from $34.0 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $115.2 million in Q1 2021, with the low at $14.2 million in Q2 2024.
• The 5-year median for Liabilities and Shareholders Equity is $51.0 million (2023), against an average of $56.8 million.
• The sharpest annual moves came in 2021 and 2024: Liabilities and Shareholders Equity jumped 274.66% in 2021, then slumped 72.22% in 2024.
• Iterum Therapeutics' Liabilities and Shareholders Equity stood at $91.5 million in 2021, then fell by 26.97% to $66.8 million in 2022, then slumped by 60.71% to $26.3 million in 2023, then jumped by 69.83% to $44.6 million in 2024, then slipped by 27.12% to $32.5 million in 2025.
• Business Quant data shows ITRMF's Liabilities and Shareholders Equity at $32.5 million in Q3 2025, $34.0 million in Q2 2025, and $33.0 million in Q1 2025.